Company Overview

ARS Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including anaphylaxis. The company operates within the biotechnology and specialty pharmaceutical industries, with a primary emphasis on needle-free emergency therapies. Its core commercial product is neffy, an intranasal epinephrine spray designed as an alternative to traditional injectable epinephrine auto-injectors for the emergency treatment of Type I allergic reactions, including anaphylaxis. Revenue generation is currently centered on commercialization activities tied to neffy, regulatory milestones, licensing arrangements, and related commercialization partnerships.

The company was founded to address barriers associated with injectable epinephrine products, including needle aversion, portability, and inconsistent patient usage during emergencies. ARS Pharmaceuticals evolved from a clinical-stage development company into a commercial-stage organization following U.S. regulatory approval of neffy in 2024. The company’s strategic positioning is based on proprietary intranasal drug delivery technology intended to improve accessibility and patient adherence in emergency allergy treatment settings.

Business Operations

ARS Pharmaceuticals conducts operations primarily through development, regulatory, commercialization, and medical affairs activities tied to its intranasal epinephrine platform. The company’s principal operating focus is the commercialization of neffy, which utilizes a proprietary intranasal formulation and delivery system for epinephrine administration. Historically, the company generated limited revenue prior to commercialization and relied substantially on capital markets financing, licensing arrangements, and collaboration agreements to support operations.

The company maintains commercial and development activities primarily in the United States, while also pursuing international expansion through partnerships and licensing arrangements. ARS Pharmaceuticals has entered into commercialization and regional licensing collaborations for markets outside the U.S., including agreements involving allergy-focused pharmaceutical distributors and regional commercialization partners. The company’s intellectual property portfolio includes patents related to intranasal epinephrine formulation technology and delivery mechanisms intended to support competitive differentiation in the emergency allergy treatment market.

Strategic Position & Investments

ARS Pharmaceuticals’ strategic direction is centered on expanding adoption of needle-free emergency epinephrine treatment and increasing global market penetration for neffy. Growth initiatives include physician education, payer access expansion, school and community emergency preparedness programs, and additional regulatory approvals in international markets. The company has also explored lifecycle management opportunities related to dosage formats and broader allergy-related indications tied to intranasal delivery technology.

The company has invested substantially in clinical development, regulatory approvals, and commercialization infrastructure following the approval of neffy. Strategic partnerships have been used to support regional market access, distribution, and commercialization outside the United States. ARS Pharmaceuticals operates primarily as a focused commercial biotechnology company rather than a diversified pharmaceutical holding structure, and public disclosures do not indicate a broad portfolio of subsidiary operating businesses. Data regarding additional material portfolio investments or diversified holdings is inconclusive based on available public sources.

Geographic Footprint

ARS Pharmaceuticals is headquartered in San Diego, California, and maintains its primary operational presence in the United States. The company’s principal commercial focus remains the U.S. allergy and anaphylaxis treatment market, particularly among patients, caregivers, schools, healthcare providers, and emergency preparedness organizations. U.S. regulatory approval of neffy represented a significant milestone in establishing domestic commercial operations.

Internationally, the company has pursued expansion through licensing and distribution arrangements in selected regions, including parts of Europe and other international markets where regulatory submissions or partnership discussions have been disclosed publicly. While the company does not currently maintain the broad multinational operating footprint of larger pharmaceutical companies, it has established strategic relationships intended to support future global commercialization and market access initiatives.

Leadership & Governance

ARS Pharmaceuticals is led by an executive team with backgrounds in biotechnology commercialization, drug development, allergy therapeutics, and pharmaceutical operations. Leadership strategy has emphasized commercialization discipline, regulatory execution, and expanding access to needle-free treatment options for severe allergic reactions. Public filings and investor communications indicate a strategic focus on building a differentiated allergy emergency treatment platform while scaling commercial operations following product approval.

Key executives include:

• Richard Lowenthal – Co-Founder, President, and Chief Executive Officer
• Brian Dorsey, M.D. – Chief Medical Officer
• Philippe Dubois – Chief Financial Officer
• Sarah Sell – Chief Commercial Officer
• Eric Karas – Chief Legal Officer and Secretary

The company’s governance framework includes oversight by a board of directors with experience in biotechnology, pharmaceuticals, finance, and healthcare commercialization. Corporate governance practices and executive responsibilities are disclosed through SEC filings, including annual reports, proxy statements, and investor presentations.